Automatic Website Traffic RSS

AI, DEI, and…GLPs? Here’s what the tech elite were buzzing about at South by Southwest

Mostly everyone, including me, said no. My favorite question was, which will have a greater impact on the U.S. economy in the coming years, AI or GLPs (weight loss medications such as Wegovy and ... read more

GLPS dismisses early due to power outage

GRAND LEDGE, Mich. (WLNS) — Consumers Energy has reported that most of its Grand Ledge customers have power again, following a power outage earlier on Thursday morning. Grand Ledge Public ... read more

How has this $25 billion fund beaten the S&P 500? Patience — and preparing for ‘the next big thing.’

“We think there will be a long period during which they surprise investors with the size of the market for GLPs,” Moberg said. When asked about Lilly’s competitor in the GLP-1 drug space ... read more

India’s Biocon eyes a pie of $100 billion market as patents for blockbuster weight loss drugs start to expire

The Bengaluru-based firm has scored an early win among its peers with the UK approval for the first generic version of liraglutide injectible, which is losing patent protection in November ... read more

Doc Flung From Trailer Dies; Viral Hepatitis Deaths Rise; Suicidal Thoughts and GLPs

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Will an 1864 law banning abortion take effect in Arizona ... read more

Obesity drugs aren’t always forever. What happens when you quit?

Many researchers think that Wegovy and Ozempic should be taken for life, but myriad factors can force people off them. read more

What Happens When You Quit Ozempic or Wegovy?

People can also try anti-obesity medications that work in other ways, such as orlistat, which reduces how much dietary fat gets absorbed by the body.But “by the time we’ve gotten to the GLPs ... read more

Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly

“What we are trying to do is result in significant weight loss without losing muscle mass, which is what we see with the GLPs,” CEO Vlad Coric told CNBC. So Biohaven is developing ... read more

What’s In Store For Consumer Healthcare In 2024? Experts Weigh In

We saw it with Oura and Natural Rhythms. We are now seeing wearables be integrated with diabetes care at Glucare, on top of GLPs. There’s so much more to come.” Whatever the disease ... read more

Impersonation, open voting: What some parts of Kerala see during polls?

THIRUVANANTHAPURAM : "You are just a presiding officer. You need to act accordingly. Otherwise, we will chop off your hands and legs!” This was the threat ... read more

SSK’s summer reading programme improves Malayalam skills of young students

Thiruvananthapuram Fathima Husna and other Class I and II students in Kerala receive storybooks for summer reading program. read more

How has this $25 billion fund beaten the S&P 500? Patience - and preparing for 'the next big thing.'

"We think there will be a long period during which they surprise investors with the size of the market for GLPs," Moberg said. When asked about Lilly's competitor in the GLP-1 drug space - Novo ... read more